Project Grant 2014327

Grant Award Summary Molecular Intelligence LLC received a $435,882 Small Business Innovation Research (SBIR) Phase I project grant from the National Institute of General Medical Sciences under the Biomedical Research and Research Training program (CFDA 93.859), effective September 1, 2025, with completion targeted for February 28, 2027. The award funds development of advanced artificial intelligence-powered software tools designed to model receptor-ligand interactions from cryo-electron...

This SBIR Phase I award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $273,550 to Biocognon LLC for the development of a combinatorial platform to discover improved molecular recognition components for use in therapeutic and diagnostic antibodies. The project aims to utilize synthetic biology, next-generation DNA sequencing, and computational biology to efficiently generate and screen libraries of antibody...

This $274,990 Small Business Innovation Research (SBIR) Phase I award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships) supports the development of a physics-based machine learning platform for predicting the crystal structure of small drug molecules. The technology aims to accelerate and reduce the cost of early-stage pharmaceutical research and development by computationally analyzing the crystal structure properties that determine key...

The U.S. National Science Foundation (NSF) awarded a $303,864 Phase I Small Business Innovation Research (SBIR) grant under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Core Biotherapeutics, Inc. (UEI N9FGZ15RQGJ4) located in Ladera Ranch, CA. The project aims to develop a platform for discovering therapeutic drug candidates that can modulate molecular networks driving diseases, with the potential to produce disease-modifying effects for neurodegenerative...

Federal Grant Award Summary Peptiforge, Inc. received a $306,872 Phase 1 Small Business Innovation Research (SBIR) Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) for the period of September 1, 2025 through August 31, 2026. The company is developing an accelerated platform technology for rapid protein binder discovery, designed to be at least 50 times faster and 50 times less expensive than...

This $274,797 National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award to Deepseq.ai LLC supports the development of an AI-driven platform to accelerate the identification of highly developable single-domain antibodies for drug discovery. The proposed work aims to create a multimodal AI model capable of rapidly screening large libraries to generate lead molecules with favorable binding affinity, stability, and manufacturability. This project...

This Cooperative Agreement award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program provides $999,878 to Akttyva Therapeutics, Inc., a small business located in Watertown, MA, to develop an AI-assisted drug discovery platform to identify existing drugs and new chemical entities capable of repairing vascular permeability barriers. The project aims to address unmet clinical needs for conditions like acute respiratory distress...

This $275,000 Small Business Innovation Research (SBIR) Phase I award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program supports the development of a label-free, high-resolution, high-throughput protein screening platform called Vibrational Spectroscopy with Metasurface Optics (VISMO). The technology aims to enable simultaneous, minute-scale measurement of millions of protein samples, which would dramatically improve the lengthy and costly cycles...

Federal Grant Award Summary Robust Diagnostics LLC received $404,032 in Project Grant funding from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) for the period of September 1, 2025 through August 31, 2026. The award supports development of a machine learning-powered peptide discovery platform designed to accelerate the identification of peptide ligands for peptide-drug conjugates (PDCs). The platform...

Hidalga Technologies, Inc. received a $304,935 Small Business Innovation Research (SBIR) Phase I Project Grant from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) for the period of October 1, 2025 through September 30, 2026. The company will develop and validate an artificial intelligence (AI)-driven platform designed to automate prior authorization (PA) processing workflows in oncology specialty healthcare. The platform...